This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sheoran, A. S. Articles by Tzipori, S. Search for Related Content PubMed PubMed Citation Articles by Sheoran, A. S. Articles by Tzipori, S.

 Previous Article  |  Next Article 

Infection and Immunity, June 2003, p. 3125-3130, Vol. 71, No. 6
0019-9567/03/$08.00+0     DOI: 10.1128/IAI.71.6.3125-3130.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Stx2-Specific Human Monoclonal Antibodies Protect Mice against Lethal Infection with Escherichia coli Expressing Stx2 Variants

Division of Infectious Diseases, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts 01536,¹ Department of Mathematics, Southeast Missouri State University, Cape Girardeau, Missouri 63701²

Received 11 December 2002/ Returned for modification 14 February 2003/ Accepted 28 February 2003

Shiga toxin-producing Escherichia coli (STEC) strains are responsible for causing hemolytic-uremic syndrome (HUS), and systemic administration of Shiga toxin (Stx)-specific human monoclonal antibodies (HuMAbs) is considered a promising approach for prevention or treatment of the disease in children. The goal of the present study was to investigate the ability of Stx2-specific HuMAbs to protect against infections with STEC strains that produce Stx2 variants. Dose-response studies on five HuMAbs, using the mouse toxicity model, revealed that only the three directed against the A subunit were protective against Stx2 variants, and 5C12 was the most effective among the three tested. Two HuMAbs directed against the B subunit, while highly effective against Stx2, were ineffective against Stx2 variants. In a streptomycin-treated mouse model, parenteral administration of 5C12 significantly protected mice up to 48 h after oral bacterial challenge. We conclude that 5C12, reactive against the Stx2 A subunit, is an excellent candidate for immunotherapy against HUS and that antibodies directed against the A subunit of Stx2 have broad-spectrum activity that includes Stx2 variants, compared with those directed against the B subunit.

Editor: J. D. Clements

This article has been cited by other articles:

• Eaton, K. A., Friedman, D. I., Francis, G. J., Tyler, J. S., Young, V. B., Haeger, J., Abu-Ali, G., Whittam, T. S. (2008). Pathogenesis of Renal Disease Due to Enterohemorrhagic Escherichia coli in Germ-Free Mice. Infect. Immun. 76: 3054-3063 [Abstract] [Full Text]  
• Krautz-Peterson, G., Chapman-Bonofiglio, S., Boisvert, K., Feng, H., Herman, I. M., Tzipori, S., Sheoran, A. S. (2008). Intracellular Neutralization of Shiga Toxin 2 by an A Subunit-Specific Human Monoclonal Antibody. Infect. Immun. 76: 1931-1939 [Abstract] [Full Text]  
• Sheoran, A. S., Feng, X., Singh, I., Chapman-Bonofiglio, S., Kitaka, S., Hanawalt, J., Nunnari, J., Mansfield, K., Tumwine, J. K., Tzipori, S. (2005). Monoclonal Antibodies against Enterocytozoon bieneusi of Human Origin. CVI 12: 1109-1113 [Abstract] [Full Text]  
• Sheoran, A. S., Chapman-Bonofiglio, S., Harvey, B. R., Mukherjee, J., Georgiou, G., Donohue-Rolfe, A., Tzipori, S. (2005). Human Antibody against Shiga Toxin 2 Administered to Piglets after the Onset of Diarrhea Due to Escherichia coli O157:H7 Prevents Fatal Systemic Complications. Infect. Immun. 73: 4607-4613 [Abstract] [Full Text]  
• Akiyoshi, D. E., Rich, C. M., O'Sullivan-Murphy, S., Richard, L., Dilo, J., Donohue-Rolfe, A., Sheoran, A. S., Chapman-Bonofiglio, S., Tzipori, S. (2005). Characterization of a Human Monoclonal Antibody against Shiga Toxin 2 Expressed in Chinese Hamster Ovary Cells. Infect. Immun. 73: 4054-4061 [Abstract] [Full Text]  
• Tzipori, S., Sheoran, A., Akiyoshi, D., Donohue-Rolfe, A., Trachtman, H. (2004). Antibody Therapy in the Management of Shiga Toxin-Induced Hemolytic Uremic Syndrome. Clin. Microbiol. Rev. 17: 926-941 [Abstract] [Full Text]